More controversy than ever - Challenges and promises towards personalized treatment of gastric cancer

Annals of Surgical Oncology

Volumn 15, Issue 4, 2008, Pages 956-960

  Liakakos, Theodore ^a   Roukos, Dimitrios H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; EPIRUBICIN; FLUOROURACIL;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; EDITORIAL; GASTRECTOMY; HUMAN; LAPAROSCOPY; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; GASTRECTOMY; HUMANS; NEOPLASM STAGING; STOMACH NEOPLASMS;

EID: 40549135647     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9798-5     Document Type: Editorial

References (41)

1. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-20
2. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20
3. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730
4. Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell 2007;128:225-31
5. Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nature Rev Canc 2006;6:735-41
6. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8
7. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007;39:347-351
8. Wood LD, Parsons DW, Jones S. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108-1113
9. ENCODE Project Consortium, Birney E, Stamatoyannopoulos JA, Dutta A, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007;447:799-816
10. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
11. Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer - integrating current standards and new technologies. Expert Rev Mol Diagn 2008;8:29-39
12. Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005;2:98-107
13. Sano T. Tailoring treatments for curable gastric cancer. Br J Surg 2007;94:263-4
14. Roukos DH. Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 1998;80:16-24
15. Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit?. Ann Surg Oncol 2000;7:253-5
16. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;366:2087-106
17. Punglia RS, Morrow M, Winer EP, et al. Local therapy and survival in breast cancer. N Engl J Med 2007;356:2399-405
18. Siewert JR, Bottcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228:449-61
19. Brennan MF. Current status of surgery for gastric cancer: a review. Gastric Cancer 2005;8:64-70
20. Patel PR, Mansfield PF, Crane CH, et al. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer 2007;110:989-95
21. Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery?. Ann Surg Oncol 2002;9:220-1
22. Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?. Ann Surg Oncol 2007;14:2691-5
23. Roukos DH, Lorenz M, Karakostas K, et al. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2000;84:1602-9
24. Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States?. Ann Surg Oncol 2004;11:727-30
25. Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002;81:59-62
26. Briasoulis E, Liakakos T, Dova L, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006;6:931-9
27. Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007;6:308-12
28. Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2008; 358:197, authors reply 198
29. Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007;245:873-9
30. Barber M, Fitzgerald RC, Caldas C. Familial gastric cancer - aetiology and pathogenesis. Best Pract Res Clin Gastroenterol 2006;20:721-34
31. Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002;9:607-609
32. Chung DC, Yoon SS, Lauwers GY, Patel D. Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer. N Engl J Med 2007;357:283-91
33. Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357:1555-6; author reply 1556
34. Roukos DH, Agnanti NJ, Paraskevaidis E, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002;9:941-3
35. Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 2007 Oct 17; [Epub ahead of print]; DOI: 10.1245/s10434-007-9612-4
36. Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004;11:1030-4
37. Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007;4:578-90
38. Gewin V. Missing the mark. Nature 2007;449:770-1
39. Wu CW, Hsiung SA, Lo, et al. Nodal dissection for patients with gastric cancer: a randomised trial. Lancet Oncol 2006;7:309-15
40. Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 2004;11:127-129
41. Lee JH, Kim YW, Ryu KW, A phase-II clinical trial of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for gastric cancer patients. Ann Surg Oncol 2007 Aug 20; [Epub ahead of print]